BIO-TECHNE CORP's ticker is TECH and the CUSIP is 09073M104. A total of 336 filers reported holding BIO-TECHNE CORP in Q3 2019. The put-call ratio across all filers is 5.05 and the average weighting 0.2%.
About BIO-TECHNE CORP
Bio-Techne Corp is a leading provider of innovative life science research tools and diagnostic solutions. The company is headquartered in Minneapolis, Minnesota, and has operations in over 50 countries worldwide. Bio-Techne's products and services are used by researchers and clinicians in a wide range of fields, including cancer research, stem cell research, and immunology.
Bio-Techne's success is due in large part to its commitment to innovation and customer service. The company invests heavily in research and development, and has a team of over 1,000 scientists working to develop new products and technologies. Bio-Techne also has a strong focus on customer service, with a dedicated team of technical support specialists available to assist customers with any questions or issues they may have.
In addition to its research tools and diagnostic solutions, Bio-Techne also has a growing portfolio of clinical diagnostic products. The company's Exosome Diagnostics subsidiary is a leader in the development of liquid biopsy tests for cancer diagnosis and monitoring.
Bio-Techne's leadership team is comprised of experienced executives with a track record of success in the life sciences industry. Charles Kummeth, the company's CEO, has been with Bio-Techne since 2013 and has overseen significant growth and expansion during his tenure.
Overall, Bio-Techne is a company with a strong reputation for innovation, customer service, and leadership in the life sciences industry. With a growing portfolio of products and services, the company is well-positioned for continued success in the years to come.
It's important to note that this information is for educational purposes only and has not been fact-checked. As with any investment, it's important to do your own research and consult with a financial advisor before making any investment decisions.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q3 2023 | $112 | -18.8% | 1,645 | -2.9% | 0.00% | -50.0% |
Q2 2023 | $138 | +1.5% | 1,695 | -7.4% | 0.01% | 0.0% |
Q1 2023 | $136 | -54.5% | 1,830 | -49.3% | 0.01% | -57.1% |
Q4 2022 | $299 | -99.8% | 3,606 | +567.8% | 0.01% | +133.3% |
Q3 2022 | $153,000 | -18.2% | 540 | 0.0% | 0.01% | -14.3% |
Q2 2022 | $187,000 | -63.6% | 540 | -54.4% | 0.01% | -61.1% |
Q1 2022 | $514,000 | -74.6% | 1,185 | -69.7% | 0.02% | -64.0% |
Q4 2021 | $2,020,000 | -14.1% | 3,905 | -19.6% | 0.05% | -42.5% |
Q3 2021 | $2,351,000 | +1.8% | 4,855 | -5.4% | 0.09% | +29.9% |
Q2 2021 | $2,310,000 | +35.4% | 5,130 | -4.6% | 0.07% | -17.3% |
Q4 2020 | $1,706,000 | +8.1% | 5,375 | -15.6% | 0.08% | -6.9% |
Q3 2020 | $1,578,000 | -15.0% | 6,370 | -9.4% | 0.09% | -18.7% |
Q2 2020 | $1,856,000 | +34.8% | 7,030 | -3.2% | 0.11% | +37.2% |
Q1 2020 | $1,377,000 | -16.1% | 7,260 | -2.9% | 0.08% | -29.7% |
Q4 2019 | $1,642,000 | +10.7% | 7,480 | -1.3% | 0.11% | +6.7% |
Q3 2019 | $1,483,000 | -1.3% | 7,580 | +5.3% | 0.10% | +1.0% |
Q2 2019 | $1,502,000 | – | 7,200 | – | 0.10% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
Blue Water Life Science Advisors, LP | 46,500 | $16,119,000 | 8.75% |
Montanaro Asset Management Ltd | 93,950 | $32,567,000 | 4.90% |
Jackson Square Partners, LLC | 556,157 | $192,786,000 | 4.50% |
STONE RUN CAPITAL, LLC | 22,405 | $7,767,000 | 3.91% |
Ownership Capital B.V. | 655,654 | $227,276,000 | 3.90% |
Brown Capital Management | 839,587 | $291,034,000 | 3.90% |
Sandhill Capital Partners LLC | 97,382 | $33,757,000 | 3.61% |
DF DENT & CO INC | 684,026 | $237,111,000 | 3.34% |
Westwind Capital | 27,946 | $9,687,000 | 3.17% |
MAIRS & POWER INC | 655,930 | $227,371,000 | 2.72% |